Phenylketonuria
What's New
Last Posted: Jun 10, 2021
- Newborn Screening and Treatment of Phenylketonuria: Projected Health Outcomes and Cost-Effectiveness.
Chen Huey-Fen et al. Children (Basel, Switzerland) 2021 8(5) - Phenylketonuria.
van Spronsen Francjan J et al. Nature reviews. Disease primers 2021 7(1) 36 - A policy analysis of the national phenylketonuria screening program in Iran.
Heidari Alireza et al. BMC health services research 2021 Feb 21(1) 120 - Spectrum analysis of inborn errors of metabolism for expanded newborn screening in a northwestern Chinese population.
Zhang Ruixue et al. Scientific reports 2021 Jan 11(1) 2699 - [The neonatal screening programs in Spain.Science, research and public health, keys to their quality and effectiveness.]
Dulín Iñiguez Elena et al. Revista espanola de salud publica 2021 Jan 95 - Neonatal screening program for five conditions in Honduras.
Buckley Michelle Melissa Miralda et al. Journal of community genetics 2021 Jan - Ethical Issues Surrounding Newborn Screening.
Howell R Rodney et al. International journal of neonatal screening 2021 Jan 7(1) - [50 years of the Neonatal Screening Program in Catalonia.]
Marín Soria Jose Luis et al. Revista espanola de salud publica 2020 Dec 94 - [Evaluation and perspective of 20 years of neonatal screening in Galicia. Program results.]
Sánchez Pintos Paula et al. Revista espanola de salud publica 2020 Dec 94 - [The role of Public Health as a key to the success of the neonatal screening program in the Basque Country.]
Espada Sáenz-Torre Mercedes et al. Revista espanola de salud publica 2020 Dec 94
More
About Rare Diseases PHGKB
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Content Summary
- CDC Information (2)
- NIH Information (2)
- CDC Publications (2)
- Human Genome Epidemiologic Studies (91)
- Genomic Tests Evidence Synthesis (9)
- Genomic Tests Guidelines (10)
- Tier-Classified Guidelines (1)
- Pathogen Advanced Molecular Detection (1)
- State Public Health Genomics Programs (14)
- Reviews/Commentaries (32)
- Ethical/Legal and Social Issues (ELSI) (4)
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Eclampsia
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Glomerulonephritis
- Graves Disease
- Hemophilia
- Huntington Disease
- Microcephaly
- Myasthenia Gravis
- Phenylketonuria
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Oct 1, 2020
- Page last updated:Jun 21, 2021
- Content source: